Abstract: Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.

Abstract: Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.

Abstract: The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer.

Abstract: A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or Neisseria meningitidis.

Abstract: The invention relates to PAD inhibitors that are suitable to be used as a medicament against an autoimmune disease such as RA.

Abstract: The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and therapeutic vaccine and in a further embodiment the invention relates to the treatment or prevention of cancer or an infectious disease.

Abstract: A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or Neisseria meningitidis.

Abstract: Provided is a mAb-based method for the detection of T cell stimulatory epitopes known to be involved in CD. The method has many advantages compared to the existing methods for the detection of gluten since it is the first method that can; (i) detect T cell stimulatory epitopes of gluten; (ii) detect the epitopes separately, (iii) detect T cell stimulatory epitopes present on gliadin and glutenin homologues present in other cereals also known to be involved in CD; and (iv) detect T cell stimulatory epitopes on both intact proteins and small protein fragments. The new method is a valuable tool in the screening of basic ingredients, semi manufactured ingredients and food products that are intended to be used in the gluten free diet of CD patients. Moreover the new method can also be used for the screening of cereals and different wheat varieties for the level of toxicity for CD patients.

Abstract: The invention relates to PAD inhibitors that are suitable to be used as a medicament against an autoimmune disease such as RA.

Abstract: The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The medicaments may be administered systemically or locally.

Abstract: The invention relates to method of detecting autoantibodies from patients suffering from rheumatoid arthritis. To this end, according to the invention, at least two peptide units are used of which at least one peptide unit comprises a part not derived from (pro)filaggrin, fibrin, fibrinogen, vimentin, cytokeratin 1 and cytokeratin 9, and which peptide unit comprises the motif XG, and a peptide unit comprising the motif XnonG, wherein X is a citrulline or an analogue thereof, and nonG is an amino acid other than glycine.

Abstract: The invention relates to a peptidic compound with affinity to bacterial and fungal toxins, especially to lipopolysaccharide or lipoteichoic acid. The peptidic compound includes an amino acid sequence X1KEFX2RIVX3RIKX4FLRX5LVX6, wherein X1 represents the N-terminal part: X2 is K or E; X3 is Q or E; X4 is D or R; X5 is N or E; X6 represents the C-terminal part: an amino acid of the core sequence is optionally derivatized; the N-terminal part is acetylated, and/or the C-terminal part is amidated, and/or the sequence differs from the native amino acid sequence X1KEFKRIVQRIKDFLRNLVX6.

Abstract: The invention provides methods to exert antimicrobial effects in prophylactic or therapeutic treatment of bacterial or fungal infections employing polypeptides that have affinity to microbial and fungal toxins.

Abstract: The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer.

Abstract: The current invention provides methods for the identification of antigens and/or epitopes that are differentially displayed on TAP deficient or TAP impaired cells and are not detectably displayed on normal or TAP proficient cells. The identification and applications of these differentially presented antigens, which in this specification are referred to as TEIPP, T cell Epitopes associated with Impaired Peptide Processing, is a prime object of this invention. The invention also provides peptides comprising a TEIPP epitope obtained from the methods of the invention, which may be applied in medicaments and methods of treatment raising a T cell response against TAP deficient tumor cells or virally infected cells.

Abstract: The invention provides a GMP compatible method to chemically synthesize proteins which may be advantageously used in compositions for vaccination that are free of biological contaminants. The method uses conventional synthesis of peptides and linking these to yield synthetic proteins that preferably comprise all T cell epitopes for an antigen. Preferably an adjuvant is covalently attached to a synthetic protein to yield a fully synthetic vaccine. The invention is illustrated mainly by using HPV protein directed immunity as a model.

Abstract: The present invention identified novel epitopes from the insulin B chain which is embodied in methods and means for diagnostics and treatment of type 1 diabetes. The epitopes were found in a peptide comprising a fragment of the human insulin B chain. Using HLA-A2 tetramers having the peptide of the invention cytotoxic T-cells were found in peripheral blood cells samples from healthy individuals. The invention demonstrates that these autoreactive CTL directed against insulin B chain are able to destroy insulin producing beta-cells. Moreover, a significant proportion of cytotoxic T-cells from islet transplant recipients with recurrent autoimmunity and loss of insulin production recognized this peptide or analogue thereof. The peptide has a high affinity for the HLA-A2 allele, in particular HLA-A*0201. Based on the novel epitopes according to the invention, diagnostic and therapeutic methods and medicaments for the prevention or treatment of type 1 diabetes are provided.

Abstract: The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The medicaments may be administered systemically or locally.

Abstract: Provided is a mAb-based method for the detection of T cell stimulatory epitopes known to be involved in CD. The method has many advantages compared to the existing methods for the detection of gluten since it is the first method that can; (i) detect T cell stimulatory epitopes of gluten; (ii) detect the epitopes separately, (iii) detect T cell stimulatory epitopes present on gliadin and glutenin homologues present in other cereals also known to be involved in CD; and (iv) detect T cell stimulatory epitopes on both intact proteins and small protein fragments. The new method is a valuable tool in the screening of basic ingredients, semi manufactured ingredients and food products that are intended to be used in the gluten free diet of CD patients. Moreover the new method can also be used for the screening of cereals and different wheat varieties for the level of toxicity for CD patients.

Abstract: The present invention provides an isolated or recombinant HLA-DQ restricted T-cell receptor or functional equivalent and/or fragment thereof capable of recognizing a prolamine-derived peptide. The present invention also provides isolated, recombinant or synthetic prolamine-derived peptides involved in food-related immune enteropathy. In yet another embodiment the invention provides a diagnostic kit comprising an isolated or recombinant HLA-DQ restricted T-cell receptor according to the invention or host cell comprising a T-cell receptor according to the invention or an antibody according to the invention and a suitable means of detection. Such a diagnostic kit is, for example, very useful for detecting in food, food components or samples from (suspected) patients the presence of prolamine-derived peptide involved in food-related immune enteropathy (for example: celiac sprue, tropical sprue, giardiasis or food allergies of childhood).